Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Die Durchführbarkeit und klinische Wirksamkeit der Atezolizumab-Konsolidierungsbehandlung bei DLBCL mit hohem Risiko (IPI > 2). (HO151DLBCL)

18. September 2026 aktualisiert von: Stichting Hemato-Oncologie voor Volwassenen Nederland

Eine Phase-II-Studie zur Bewertung der Durchführbarkeit und klinischen Wirksamkeit einer Atezolizumab-Konsolidierungsbehandlung bei diffusem großzelligem B-Zell-Lymphom mit hohem Risiko

The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with only 15% of patients achieving a long remission. Therefore, additional therapy in first line treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1 inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab, this study examines the efficacy and toxicity of atezolizumab as consolidation treatment after R-CHOP induction in DLBCL patients at high risk of relapse.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

109

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Antwerp, Belgien
        • BE-Antwerpen Edegem-UZA
      • Antwerp, Belgien
        • BE-Antwerpen-ZNASTUIVENBERG
      • Bruges, Belgien
        • BE-Brugge-AZBRUGGE
      • Leuven, Belgien
        • BE-Leuven-UZLEUVEN
      • Roeselare, Belgien
        • BE-Roeselare-AZDELTA
      • 's-Hertogenbosch, Niederlande
        • NL-Den Bosch-JBZ
      • Amersfoort, Niederlande
        • NL-Amersfoort-MEANDERMC
      • Amsterdam, Niederlande
        • NL-Amsterdam-OLVG
      • Amsterdam, Niederlande
        • NL-Amsterdam-VUMC
      • Apeldoorn, Niederlande
        • NL-Apeldoorn-GELREAPELDOORN
      • Breda, Niederlande
        • NL-Breda-AMPHIA
      • Delft, Niederlande
        • NL-Delft-RDGG
      • Dordrecht, Niederlande
        • NL-Dordrecht-ASZ
      • Ede, Niederlande
        • NL-Ede-ZGV
      • Eindhoven, Niederlande
        • NL-Eindhoven-CATHARINA
      • Eindhoven, Niederlande
        • NL-Eindhoven-MAXIMAMC
      • Enschede, Niederlande
        • NL-Enschede-MST
      • Groningen, Niederlande
        • NL-Groningen-UMCG
      • Hilversum, Niederlande
        • NL-Hilversum-TERGOOI
      • Hoofddorp, Niederlande
        • NL-Hoofddorp-SPAARNEGASTHUIS
      • Leeuwarden, Niederlande
        • NL-Leeuwarden-MCL
      • Leiden, Niederlande
        • NL-Leiden-LUMC
      • Maastricht, Niederlande
        • NL-Maastricht-MUMC
      • Nieuwegein, Niederlande
        • NL-Nieuwegein-ANTONIUS
      • Nijmegen, Niederlande
        • NL-Nijmegen-CWZ
      • Rotterdam, Niederlande
        • NL-Rotterdam-ERASMUSMC
      • Rotterdam, Niederlande
        • NL-Rotterdam-MAASSTADZIEKENHUIS
      • Sittard, Niederlande
        • NL-Sittard-Geleen-ZUYDERLAND
      • The Hague, Niederlande
        • NL-Den Haag-HAGA
      • Tilburg, Niederlande
        • NL-Tilburg-ETZ
      • Utrecht, Niederlande
        • NL-Utrecht-UMCUTRECHT
      • Zwolle, Niederlande
        • NL-Zwolle-ISALA

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18-75 (inclusive) years
  • Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the World Health Association (WHO) classification, revision 2016
  • Ann Arbor stages II-IV
  • WHO performance status 0 - 1
  • International Prognostic Index (IPI) ≥ 3 at diagnosis
  • Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria

Of note:

  1. Rituximab may have been administered either intravenously or subcutaneously. A rituximab biosimilar may have been used when it is approved for the indication of DLBCL.

  2. Patients should have received at least 6 cycles R-CHOP. Dose reductions for vincristine are allowed during R-CHOP. Dose reductions because of bone marrow toxicity are allowed but cannot exceed >15% of cumulative dose of doxorubicin and cyclophosphamide.

  3. Central nervous system prophylaxis (MTX) by intrathecal therapy or IV is allowed.

  4. Fludeoxyglucose Positron Emission Tomography (18F-FDG-PET) scan should have been made 4-8 weeks after last induction cycle

  5. Histologically confirmed false positive EoT PET-scans are eligible.

    • Negative pregnancy test at study entry
    • Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
    • Patient is capable of giving a written informed consent

    Exclusion Criteria:

    Diagnosis

    • All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016, including:

    - High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or BCL6. Please note that patients with an isolated MYC translocation or an isolated BCL2 translocation or an isolated BCL-6 translocation are eligible (single hit translocation).

    • Testicular large B-cell lymphoma
    • Primary mediastinal B cell lymphoma
    • Transformed indolent lymphoma
    • Post-transplant lymphoproliferative disorder

    Organ dysfunction

    • Clinical signs of severe pulmonary dysfunction
    • Clinical signs of heart failure (New York Heart Association (NYHA) classification II-IV)
    • Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
    • Myocardial infarction during the last 6 months
    • Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min

    Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:

    CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females)/(0.815 x serum creatinine [μmol/L])

    • Inadequate hematological function: hemoglobin < 5.5 mmol/L Absolute Neutrophil Count (ANC) < 1.0x10↑9/L or platelets < 75x10↑9 /L

    • Signs or known history of bleeding disorder.
    • Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.
    • Clinical signs of severe cerebral dysfunction
    • Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
    • Major surgery within the last 4 weeks

    Known or suspected infection • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks of the start of Cycle 1. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay

    • Patients known to be Human Immuno-deficiency Virus (HIV)-positive

    • Active chronic hepatitis B or C infection
    • Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab

    Auto-immune • Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

    The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.

    • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computer tomography (CT) scan at screening.
    • Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
    • Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednisone/prednisolone

    General

    • Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)

    • Current participation in another clinical trial interfering with this trial

    • History of active cancer during the past 5 years, except basal cell carcinoma of the skin, stage 0 cervical carcinoma or carcinoma in situ (for which no systemic treatment was indicated)

    • Life expectancy < 6 months

    • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule

    Prior treatment

    • Prior treatment with Atezolizumab, or anti-programmed cell death protein-1 (anti PD-1) or PDL-1 antibodies.
    • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4 therapeutic antibodies.
    • Treatment with systemic immunostimulatory agents (including but not limited to IFN, interleukin [IL]-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.
    • Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Atezolizumab

18 cycles atezolizumab followed by 12 months of observation

Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation

Andere Namen:
  • Tecentriq
  • L01XC

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first.
Zeitfenster: 2 year after inclusion last patient

To evaluate the 2-year DFS for patients in complete metabolic remission after R-CHOP induction

2 year after inclusion last patient

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
(Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire.
Zeitfenster: 2 years after inclusion last patient

To evaluate toxicity and assess the relation of adverse events in time to recovery of the T-cell repertoire.

2 years after inclusion last patient
Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive.
Zeitfenster: 2 years after inclusion last patient

To evaluate the 2-year OS.

2 years after inclusion last patient
The relationship between MRD status at the end-of-induction and end-of-consolidation therapy.
Zeitfenster: 2 years after inclusion last patient

To evaluate MRD status at the end of induction therapy, at various time points during consolidation treatment and at the end of consolidation.

2 years after inclusion last patient
The relation between MRD conversion and 2-years DFS and OS.
Zeitfenster: 2 years after inclusion last patient

To evaluate if there is a relation between MRD conversion and 2-years DFS and OS.

2 years after inclusion last patient
The relation between the T-cell and NK cell repertoire and adverse events.
Zeitfenster: 2 years after inclusion last patient

To evaluate the recovery of the T-cell and NK cell repertoire after induction therapy and at various time points during consolidation treatment in relation to toxicity and efficacy.

2 years after inclusion last patient

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Atezolizumab spinal fluid concentration as assessed by spinal fluid measurements will be performed in patients receiving atezolizumab.
Zeitfenster: 2 years after inclusion last patient

To assess the crossing of the blood-brain barrier of atezolizumab by measuring atezolizumab concentrations in het cerebrospinal fluid.

2 years after inclusion last patient

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: M. Nijland, PhD/MD, NL-Groningen-UMCG

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. August 2018

Primärer Abschluss (Tatsächlich)

18. Januar 2024

Studienabschluss (Geschätzt)

1. Januar 2027

Studienanmeldedaten

Zuerst eingereicht

23. Februar 2018

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. März 2018

Zuerst gepostet (Tatsächlich)

13. März 2018

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • HO151
  • 2017 (US NIH Stipendium/Vertrag)
  • 2017-002605-35 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .